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Background: The interaction between neutrophils and platelets may be important in the modulation of
pulmonary haemodynamics under systemic inflammatory conditions. A study was undertaken to examine
whether antiplatelet agents inhibit platelet-neutrophil adherence and ameliorate the pulmonary
haemodynamic response to fMLP by inhibiting thromboxane release in endotoxin primed lungs. fMLP
stimulates neutrophils but not platelets; however, thromboxane synthesis in neutrophils is very low.
Methods: Rats were pretreated with either cilostazol (300 mg/kg) or aspirin (50 mg/kg) before endotoxin
priming (5 mg/kg). Platelets in the lung were identified by fluorescent immunohistochemistry. Platelet-
neutrophil adherence was analysed by flow cytometry of the lung vascular flush. The effect of fMLP
(1026 M) on thromboxane release, lung weight (an indicator of pulmonary vasoconstriction), and lung
filtration coefficient was determined in an isolated lung system perfused at a constant pressure difference.
Results: Endotoxin induced platelet accumulation and platelet-neutrophil adherence in the lung capillary
were completely inhibited by cilostazol and aspirin while neutrophil recruitment was not affected. The fMLP
challenge caused a significant increase in thromboxane B2 levels in endotoxin primed lungs. The fMLP
induced decrease in lung weight was enhanced by endotoxin priming (from 24.9 to 263.9 mg, 95% CI of
mean difference 299.5 to 210.5 mg, p,0.05). The fMLP induced increase in the lung filtration coefficient
was also enhanced by endotoxin priming (from 0.63 to 2.40 mg/min/cm H2O/g, 95% CI of mean
difference 1.17 to 2.37 mg/min/cm H2O/g, p,0.05). Treatment with cilostazol and aspirin completely
inhibited the enhanced pulmonary haemodynamic response to fMLP.
Conclusion: The neutrophil–platelet interaction is of critical importance in the modulation of pulmonary
haemodynamics via thromboxane.
I
t is well known that neutrophils are primed by inflamma-
tory substances such as endotoxin and are ready in lung
capillaries to respond to an enhanced release of a wide
array of inflammatory mediators by second stimulation.1–3
Primed neutrophils may be identified in patients under
systemic inflammatory conditions such as sepsis or following
extensive trauma and surgery—indications with a high risk
for the subsequent development of acute lung injury.4
Although neutrophils play an important role in the
pathophysiology of acute lung injury, interaction with
platelets may potentiate the production of eicosanoids such
as thromboxane, thereby altering the pulmonary haemody-
namic response to second stimulation. Voelkel et al5 reported
that N-formyl-L-methionyl-L-leucyl-L-phenylalanine (fMLP),
a neutrophil chemotactic peptide, causes strong vasoconstric-
tion and oedema via thromboxane which is probably released
from cells trapped in lung capillaries of endotoxin primed
rats.6 They found cell sedimentation composed not only of
neutrophils, but also of platelets, in the lung capillaries of
endotoxin primed rats.6 However, neutrophils alone do not
explain the production of high levels of thromboxane in the
lung. fMLP stimulates neutrophils but not platelets;7 8
however, the activity of thromboxane synthesis in neutro-
phils is very low.9
fMLP stimulated neutrophils may produce thromboxane in
coordination with platelets, the most important source in
vivo. It has been shown that the neutrophil–platelet interac-
tion is critical in the production of eicosanoids.8 10 11
Neutrophils and platelets are known to contact via platelet
P-selectin and neutrophil b2 integrins (CD11b/CD18).
12 13 In
this study we sought to examine whether endotoxin priming
enhances the adherence of neutrophils and platelets in the
lung capillaries and, if so, whether interruption of the
neutrophil–platelet interaction with antiplatelet agents ame-




Specific pathogen free male Sprague-Dawley rats weighing
300–350 g were used in this study (n = 90). All animals
received humane care in compliance with the guidelines from
the University Committee on Animal Resources, Tohoku
University, Sendai, Japan. All animal experiments were
conducted in accordance with the ‘‘Principle of Laboratory
Animal Care’’ formulated by the Institute of Laboratory
Animal Resources and the ‘‘Guide for the Care and Use of
Laboratory Animals’’ prepared by the Institute of Laboratory
Animal Resources and published by the National Institute of
Health.
Experimental protocols
Rats were pretreated with two different types of antiplatelet
agents—cilostazol, a selective inhibitor of the type III
phosphodiestalase cilostazol,14 and aspirin. Cilostazol
(300 mg/kg; Otsuka Pharmaceutical, Tokyo, Japan) was
dissolved in 1 ml water and administered directly into the
stomach via a small catheter 2 hours before endotoxin
priming. Aspirin (50 mg/kg; Wako Chemical, Osaka, Japan)
was dissolved in 0.5 ml sterilised saline and intraperitoneally
injected 18 hours before endotoxin priming. Rats were then
primed by an intraperitoneal injection of E coli endotoxin
(5 mg/kg; Difco Laboratories, Detroit, MI, USA) dissolved in
1 ml sterilised saline. For control experiments, the same
amount of saline vehicle was injected.
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Myeloperoxidase (MPO) assay
At 18 hours following endotoxin priming, rats were anaes-
thetised with pentobarbital sodium (50 mg/kg intraperitone-
ally) and ventilated manually using a 10 ml syringe via a
tracheostomy. After a median sternotomy, heparin sodium
(200 U) was administered directly into the right ventricular
cavity. The abdominal aorta and inferior vena cava were then
cut at the diaphragm. The pulmonary artery was cannulated
and both lungs were cleared of blood by flushing them with
50 ml saline at a pressure of 15 cm H2O at room temperature.
The right lung was weighed and homogenised in 0.02%
cetyltrimethylammonium bromide (CTAB) solution (Sigma,
St Louis, MO, USA) in 50 mM potassium phosphate buffer at
pH 6.0 on ice. The homogenate was centrifuged at 12 000g
for 15 minutes at 4 C̊, the supernatant decanted, and the
pellet weighed and resuspended in CTAB solution. The
suspension was freeze thawed three times, followed by
repeated sonication for 30 second bursts with an output of
30 Watts. The lung suspension was centrifuged at 12 000g
for 15 minutes at 4 C̊ and the supernatant (S1) collected.
The pellet was further resuspended in CTAB solution,
freeze thawed, sonicated, and centrifuged to obtain the
second supernatant (S2). In our preliminary experiments
we found that our samples had very low MPO activity
following further permeabilisation steps (S3, S4 and S5),
whereas the mixture of S1 and S2 recovered more than 85%
of total MPO activity. A mixture of both S1 and S2 served as
a sample for the lung MPO assay. MPO activity was
determined by chemiluminescence using a cypridina
luciferin analogue, 2-methyl-6-(p-methoxyphenyl)-3,7-dihy-
droimidaz[1,2-a]pyrazin-3-one hydrochloride (MCLA; Tokyo
Kasei Kogyo, Tokyo, Japan) as a luminescence reagent.
Immuohistochemistry
The flushed left lung was immediately frozen fixed in liquid
nitrogen and 3 mm tissue blocks were sliced. The tissue
sections were preincubated with 10% non-immunised goat
serum for 20 minutes and incubated with fluorescein
isothiocyanate (FITC) labelled rabbit polyclonal anti-rat
platelet antibody (Accurate, Westbury, NY, USA) at a dilution
of 1:50 for 30 minutes at room temperature. The antigen-
antibody complex was visualised via a fluorescent microscope
at 450–490 nm of the emission wavelength. For a negative
control, FITC labelled normal rabbit IgG (Santa Cruz
Biotechnology, Santa Cruz, CA, USA) was used instead of
the antibody and no specific immunoreactivity was detected
in any lung section.
Flow cytometry
Flow cytometry was performed on the cells obtained by
flushing the lungs. The pulmonary artery and the left
ventricle were cannulated. Both lungs were cleared of blood
by flushing with 50 ml Earle’s Balanced Salt Solution (EBSS)
at 37 C̊ via the pulmonary artery, then further flushed in a
retrograde fashion with 200 ml prewarmed calcium free
Hank’s Balanced Salt Solution (HBSS) containing 1 mM
EDTA. The lung vascular flush was centrifuged at 600g for
5 minutes. The cells were resuspended in calcium free HBSS
at 105 cells/ml and reacted with FITC labelled anti-rat platelet
antibody at a dilution of 1:20 for 20 minutes at 4 C̊.
Fluorescence intensity was analysed using a flow cytometer
(Ortho Clinical Diagnostic, Raritan, NJ, USA). For a negative
control, FITC labelled normal rabbit IgG was used instead of
the antibody, and there was no significant difference in the
very low levels of non-specific fluorescent intensity between
each experimental group.
In addition, a smear of lung vascular flush was fixed with
ethanol, reacted with the antibody, and visualised via a
fluorescent microscope. The population of neutrophils in the
lung vascular flush was counted by staining with a Giemsa
solution.
Pulmonary haemodynamic response to fMLP
The pulmonary artery and left ventricle were cannulated and
the lungs were cleared of blood with EBSS as described
above. Heart-lung blocks were then removed from the thorax
and suspended via a force displacement transducer (Nihon-
Koden, Tokyo, Japan) to monitor the lung weight continu-
ously. The lungs were perfused with Krebs-Henseleit solution
(pH 7.4) containing 6% bovine albumin and saturated with a
mixed gas (N2: 74%, O2: 20%, CO2: 6%) at 37 C̊ at a constant
pressure difference where lung weight was stable during
perfusion. In most of our experiments a stable lung perfusion
was obtained at 12 cm H2O pressure on the pulmonary artery
side when the pressure in the left ventricle side was initially
fixed at 3 cm H2O. The pressures in the pulmonary circula-
tion were adjusted by raising or lowering the reservoirs
connected to the pulmonary artery and left ventricle. The
lungs were maintained in an inflated state with an airway
pressure of 2 cm H2O.
The pulmonary filtration coefficient was estimated by the
isogravimetric method15 with modifications. After 30 minutes
of baseline monitoring the pressure of the pulmonary artery
and left ventricle were simultaneously increased by raising
the reservoirs on both the pulmonary side and the left
ventricle side by 3 cm H2O for 10 minutes. Changes in lung
weight were continuously monitored during the study. Once
lung weight had returned to baseline levels, fMLP (Sigma)
was introduced into the perfusate at a final concentration of
1026 M. The fMLP challenge caused a transient decrease in
lung weight which lasted for up to 15 minutes. Since the
lungs were perfused at a constant pressure difference, the
observed decrease in lung weight may possibly represent a
change in lung capillary volume by vasoconstriction. The lung
weight returned to baseline levels within 90 minutes of the
fMLP challenge, and again the pressure in the pulmonary
artery and left ventricle were raised by 3 cm H2O for
10 minutes. The initial filtration rate of the lung capillaries
was estimated by extrapolating the linear regression of the
lung weight gain on a semilogarithmic scale to time zero. The
filtration coefficient was calculated by dividing the initial
filtration rate by the applied lung capillary pressure incre-
ment (3 cm H2O) and standardised to 1 g wet lung weight.
To inhibit thromboxane action, 1026 M of seratrodast
(Takeda Pharmaceutical, Tokyo, Japan), a thromboxane A2
receptor antagonist,16 and 1025 M of mecrofenamate
(Cayman Chemical), a cyclooxygenase inhibitor, were intro-
duced into the lung perfusate 10 minutes before the fMLP
challenge. Thromboxane B2 levels in the lung perfusate
2 hours after the fMLP challenge were determined with a
thromboxane B2 ELISA kit (Cayman Chemical, Ann Arbor,
MI, USA) according to the manufacturer’s instructions.
Data analysis
Data are presented as mean (SE) and statistical analyses were
performed initially by using analyses of variance (ANOVA)
across all groups excepting thromboxane B2 levels in the lung
perfusate, because they did not show symmetrical distribu-
tion theoretically. Only where significant differences were
found by ANOVA was it followed by a Bonferroni adjustment
to identify which groups were significantly different. The size
of effects was provided as mean differences with 95%
confidence intervals (CI). For thromboxane B2 levels, data
are presented as median with 95% CI, and statistical analyses
were performed with the Kruskal-Wallis non-parametric test.
When overall differences were identified, the Steel test was
performed to identify which groups were significantly
different. Statistical significance was defined as p,0.05.
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RESULTS
Low levels of MPO activity were detected in the lungs of
control animals. Endotoxin priming increased lung MPO
activity significantly (from 10.2 (1.3) to 46.6 (5.6)6106 cpm/
right lung, p,0.05, fig 1). However, pretreatment with
cilostazol or aspirin did not ameliorate the increased lung
MPO activity in endotoxin primed rats (49.1 (3.1) and 43.7
(2.8) 6 106 cpm/right lung, respectively; fig 1).
FITC labelled antiplatelet antibody identified no platelets
in control specimens (fig 2A) but a number of platelets were
found in lung sections obtained from endotoxin primed rats
(fig 2B). When rats were pretreated with cilostazol and
aspirin, no fluorescence immunoreactivity of platelets was
detectable (fig 2C and D). Vehicle controls for cilostazol and
aspirin did not inhibit platelet accumulation in endotoxin
primed rats.
Flow cytometry of the lung vascular flush showed that
endotoxin priming increased fluorescence intensity signifi-
cantly (from 20.0 (2.9) to 60.6 (3.7), 95% CI of mean
difference 24.6 to 56.6, p,0.05, fig 3A). Enhanced fluorescent
intensity was inhibited to control levels—that is, 33% of
endotoxin experiments—by pretreatment with cilostazol
(22.0 (3.5), p,0.05 v endotoxin, fig 3B) or aspirin (18.7
(1.8), p,0.05 v endotoxin, fig 3C). Immunocytochemistry
using FITC labelled antiplatelet antibody identified the
existence of platelets with neutrophils in the lung vascular
flush (fig 4). A smaller number of lymphocytes was found on





































Figure 1 Effect of cilostazol and aspirin on lung myeloperoxidase
(MPO) activity. Pretreatment with cilostazol or aspirin did not ameliorate
the increased lung MPO activity in endotoxin (ETX) primed rats.
Cilostazol and aspirin showed no significant influence on lung MPO
activity in rats without endotoxin priming (not shown). Mean (SE) group




Figure 2 Immunohistochemistry of platelets in lung sections. FITC labelled anti-rat platelet antibody identified no platelets in control experiments,
although very low levels of non-specific background staining outlined the alveolar wall structures (A). In contrast, a number of immunofluorescence
spots of platelets were found in lung sections obtained from endotoxin primed rats (B). Pretreatment with antiplatelet agents completely inhibited platelet
accumulation in the lung capillaries. There was no detectable platelet immunoreactivity in lungs pretreated with cilostazol (C) or aspirin (D). For
immunohistochemical examinations, the flushed left lungs were frozen fixed in liquid nitrogen. Frozen lung sections were then reacted with FITC
labelled polyclonal rabbit anti-rat platelet antibody and visualised via a fluorescence microscope at 450–490 nm of the emission wavelength. For
negative controls, FITC labelled normal rabbit IgG was used instead of anti-rat platelet antibody, and no specific immunoreactivity was detected in any
lung sections. Original magnification 6200.
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were not associated with platelets. Endotoxin priming
increased the neutrophil counts in the lung vascular flush
significantly from 0.53 (0.50) to 2.00 (0.37) 6 106 cells/lung
(p,0.05), but there was no significant difference in the
number of other cell types, mostly lymphocytes (fig 5).
Once it was established that neutrophils existed in contact
with platelets in endotoxin primed lungs and that in vivo
pretreatment with cilostazol and aspirin inhibited adherence
of platelets and neutrophils, we then examined whether
these antiplatelet agents inhibit fMLP induced thromboxane
release. The thromboxane B2 level in the lung perfusate
collected 2 hours after the fMLP challenge was very low in
control experiments, but fMLP caused a significant increase
in thromboxane B2 levels in the endotoxin primed lungs
(59 pg/ml, 95% CI 34 to 94 pg/ml v 8696 pg/ml, 95% CI 7146
to 10418 pg/ml, p,0.05, fig 6). Pretreatment with cilostazol
and aspirin completely inhibited the impact of endotoxin
priming on the fMLP induced thromboxane release (368 pg/
ml, 95% CI 92 to 771 pg/ml, p,0.05 v endotoxin, and 58 pg/
ml, 95% CI 3 to 167 pg/ml, p,0.05 v endotoxin, respectively;
fig 6).
Endotoxin priming enhanced the decrease in lung weight
induced by fMLP (from 24.9 (4.9) to –63.9 (16.0) mg, 95% CI
of mean difference –99.5 to –10.5 mg, p,0.05, fig 7). The
effect of endotoxin priming on the fMLP induced decrease in
lung weight was completely inhibited by pretreatment with
cilostazol (–6.0 (8.2) mg, p,0.05 v endotoxin) and aspirin
(24.3 (6.3) mg, p,0.05 v endotoxin, fig 7). The effect of
endotoxin priming was also completely inhibited by mecro-
fenamate (26.4 (6.3) mg, p,0.05 v endotoxin) and sera-
trodast (22.2 (3.1) mg, p,0.05 v endotoxin, fig 7).
Endotoxin priming also enhanced the increase in lung























































Figure 3 Flow cytometry of the lung vascular flush. A representative
histogram of three different measurements is shown in each group.
Endotoxin priming increased fluorescence intensity (A). The increase in
fluorescent intensity was inhibited by pretreatment with cilostazol (B) and
aspirin (C). Vehicle controls for cilostazol and aspirin showed no
inhibitory effects on fluorescence intensity (not shown). The cells in the
lung vascular flush (105 cells/ml) were reacted with FITC labelled anti-rat
platelet antibody and analysed by a flow cytometer. For negative
controls the cells were reacted with FITC labelled normal rabbit IgG; no
significant difference was seen in the very low levels of non-specific
fluorescent intensity between experimental groups.
Figure 4 Immunocytochemistry of the lung vascular flush. FITC labelled
anti-rat platelet antibody identified several platelets attached to
neutrophils. Two platelets are shown in contact with a neutrophil. A
number of neutrophils were found to exist with platelets in three different
specimens of lung vascular flush of endotoxin primed rats, while very few
neutrophils were associated with platelets in a smear obtained from
control experiments (without endotoxin priming). A smear of the lung
vascular flush was fixed with ethanol, reacted with FITC labelled
polyclonal rabbit anti-rat platelet antibody and visualised via a





















Figure 5 Neutrophil counts in the lung vascular flush. Endotoxin
priming (ETX) increased the number of neutrophils in the lung vascular
flush. There was no significant difference in the number of other cell
types, mostly lymphocytes. Neutrophils were counted by staining lung
vascular flush with a Giemsa solution. Data are shown as groups of
mean (SE) (n = 5). *p,0.05 v control by ANOVA followed by a
Bonferroni adjustment.
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2.40 (0.22) mg/min/cmH2 O/g, 95% CI of mean difference
1.17 to 2.37 mg/min/cm H2O/g, p,0.05, fig 8). Again, the
effect of endotoxin priming on the fMLP induced increase in
lung filtration coefficient was completely inhibited by
cilostazol (0.22 (0.13) mg/min/cm H2O/g, p,0.05 v endo-
toxin) and aspirin (0.15 (0.33) mg/min/cm H2O/g, p,0.05 v
endotoxin), as well as mecrofenamate (0.18 (0.18) mg/min/
cm H2O/g, p,0.05 v endotoxin) and seratrodast (0.22 (0.21)
mg/min/cm H2O/g, p,0.05 v endotoxin; fig 8).
DISCUSSION
Our first question was whether endotoxin priming enhances
adherence of neutrophils and platelets in the lung capillaries.
A marked increase in lung MPO activity confirmed that
endotoxin causes recruitment of neutrophils into the lung
capillaries. In addition, we found accumulation of a number
of platelets in the lungs of endotoxin primed rats. Some of
these platelets were found to adhere to neutrophils since flow
cytometry of the lung vascular flush showed that endotoxin
priming increased fluorescence intensity of platelets.
Although we did not separate neutrophils from other cell
types such as lymphocytes in the lung vascular flush, the cells
attached by platelets were mostly neutrophils. Fluorescent
immunocytochemistry identified several platelets on the
polymorphonuclear cells in the smear of the lung vascular
flush. In addition, the population of neutrophils in the lung
vascular flush was .80% in endotoxin primed rats. Our
results are consistent with a previous report that examined
cell sedimentation in endotoxin primed rats by electron
microscopy and found that it was composed not only of
neutrophils but also platelets, although it did not examine
the effect of antiplatelet agents.6
Once it was clear that endotoxin priming enhanced the
adherence of neutrophils and platelets in the lung capillaries,
we then determined whether pretreatment with antiplatelet
agents would interfere with the neutrophil–platelet inter-
action. Two different antiplatelet agents—cilostazol and
aspirin—were examined. Cilostazol is a selective inhibitor
of the type III phosphodiestalase14 which displays powerful
inhibition of platelet aggregation17 and has been used in the
treatment of various peripheral vascular diseases.18 Aspirin, a
classic non-selective cyclooxygenase inhibitor, has also been
widely used to prevent platelet aggregation in the lung.
Interestingly, both cilostazol and aspirin completely inhibited
the accumulation of platelets in the lung but neither had any
effect on the increased lung MPO activity. This suggests that
antiplatelet agents inhibit the adherence of neutrophils and
platelets in the lung capillaries, even though recruitment of
endotoxin primed neutrophils occurs. Flow cytometry of the
lung vascular flush showed that both cilostazol and aspirin
completely inhibited endotoxin induced adherence of neu-
trophils and platelets.
What is the physiological significance of the activity of



































Figure 6 Effect of cilostazol and aspirin on thoromboxane B2 levels in
the lung perfusate. fMLP caused a significant increase in thromboxane B2
levels. Pretreatment with cilostazol and aspirin completely inhibited the
fMLP induced thromboxane release. Vehicle controls for cilostazol and
aspirin showed no inhibition (not shown). Thromboxane B2 levels were
determined using a thromboxane B2 ELISA kit. Data are shown as
groups of median with 95% confidence interval (CI) (n = 5). *p,0.05 v
control; **p,0.05 v endotoxin experiment (ETX) (Kruskal-Wallis test














































Figure 7 Effect of cilostazol and aspirin on the weight of perfused
lungs. Endotoxin priming enhanced the decrease in lung weight induced
by fMLP (95% CI of mean difference –99.5 to –10.5 mg). The decrease
in lung weight was completely inhibited by pretreatment with cilostazol
and aspirin, as well as mecrofenamate (mecro) and seratrodast (serat).
Cilostazol, aspirin, mecrofenamate, or seratrodast had no significant
influence on lung weight in rats without endotoxin priming (not shown).
Vehicle controls for cilostazol and aspirin had no inhibition (not shown).
The lungs were perfused with Krebs-Henseleit solution at a constant
pressure difference which made lung weight stable during perfusion.
fMLP (1026 M) caused a transient decrease in lung weight which lasted
for up to 15 minutes. The decrease in lung weight induced by fMLP was
therefore considered to be representative of a decrease in lung vascular
volume due to vasoconstriction. Data are shown as mean (SE) groups of
5. *p,0.05 v control; **p,0.05 v endotoxin experiment (ETX) (ANOVA





















































Figure 8 Effect of cilostazol and aspirin on lung filtration coefficient.
Endotoxin priming also enhanced the increase in lung filtration
coefficient induced by fMLP (95% CI of mean difference 1.17 to
2.37 mg/min/cm H2O/g). The increase in lung filtration coefficient was
completely inhibited by cilostazol and aspirin, as well as by
mecrofenamate (mecro) and seratrodast (serat). Cilostazol, aspirin,
mecrofenamate, or seratrodast had no significant influence on lung
filtration coefficient in rats without endotoxin priming (not shown).
Vehicle controls for cilostazol and aspirin had no inhibition (not shown).
The lung filtration coefficient was determined before and after fMLP
challenge by the isogravimetric method15 with modification. Data are
shown as mean (SE) groups of 5. *p,0.05 v control; **p,0.05 v
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and platelets? We found that both cilostazol and aspirin
completely inhibited fMLP induced thromboxane release, so
we compared the pulmonary haemodynamic response to
fMLP in the presence and absence of antiplatelet agents.
Again, both cilostazol and aspirin completely inhibited the
fMLP induced decrease in lung weight. The magnitude of this
observed weight change is coincident with a decrease in the
lung capillary volume caused by pulmonary vasoconstriction
at precapillary sites rather than at post-capillary sites. The
decrease in lung weight lasted for 15 minutes following the
introduction of fMLP. The relatively short life time of fMLP
activity on pulmonary blood vessels also suggests the
involvement of thromboxane as the primary mediator. In
addition, two different types of thromboxane inhibitors—a
thromboxane A2 receptor antagonist seratrodast and a
cyclooxigenase inhibitor mecrofenamate—completely inhib-
ited the fMLP induced decrease in lung weight.
Our results show that fMLP, which stimulates neutrophils
but not platelets,7 8 causes pulmonary vasoconstriction via
thromboxane released from platelets. It is very likely there-
fore that the fMLP induced release of thromboxane did not
occur in neutrophils alone but was the result of coordination
with platelets. Through interactions with specific receptors
on the surface of neutrophils, fMLP activates phospholipase
A2 and metabolises phospholipids to arachidonic acids (AA).
The attached platelets may share AA with neutrophils which
can be further metabolised via cyclooxygenase and throm-
boxane synthase to thromboxane A2.
10 In addition, neutro-
phils may induce another isozyme of cyclooxygenase,
cyclooxygenase (COX)-2, by endotoxin priming19 and meta-
bolise AA to prostaglandin H2 which can also be used as a
substrate for thromboxane synthase in platelets.
Interestingly, we found that thromboxane not only caused
pulmonary vasoconstriction but also an increase in perme-
ability. Although thromboxane has been considered to
mediate pulmonary vasoconstriction and not permeability,
several lines of evidence have recently indicated that
thromboxane is capable of increasing microvascular perme-
ability in various tissues.20 21 Thromboxane activates phos-
pholipase C and increases both inositol 1,4,5-triphosphate
(IP3) production and intracellular free Ca
2+ levels via
thromboxane A2 receptor, thereby resulting in the contrac-
tion of targeted cells such as vascular smooth muscle cells.22
Thromboxane may also influence stress fibres in endothelial
cells and increases fluid movement via intercellular junc-
tions.23 We found that endotoxin priming enhanced the
impact of fMLP on the lung filtration coefficient. This
enhanced action of fMLP in the endotoxin primed lungs
was again completely inhibited by pretreatment with
cilostazol and aspirin, as well as seratrodast and mecrofena-
mate which were introduced into the lung perfusate. This
indicates that an increase in lung vascular permeability after
the fMLP challenge is a result of an enhanced release of
thromboxane.
Several experimental studies suggest that aspirin may be
beneficial in treating acute lung injury.24 25 In addition, the
efficacy of thromboxane A2 receptor antagonist has been
examined in endotoxin induced acute lung injury models.26
The results of this study appear to suggest that platelets in
the lung capillaries do not function merely as bystanders but,
more importantly, they interact with neutrophils in the
production of thromboxane which plays an important role in
the modulation of pulmonary haemodynamics under the
condition of systemic inflammatory response. We found that
the pharmacological interruption of the neutrophil–platelet
interaction ameliorated fMLP induced pulmonary vasocon-
striction and increased permeability by inhibiting thrombox-
ane release in endotoxin primed rats. We therefore suggest
that the use of antiplatelet agents may be potentially
beneficial in the treatment of acute lung injury.
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